See more : Greenrose Acquisition Corp. (GNRSW) Income Statement Analysis – Financial Results
Complete financial analysis of Impel Pharmaceuticals Inc. (IMPL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Impel Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Air Lease Corporation (AL-PA) Income Statement Analysis – Financial Results
- AB Industrivärden (publ) (IDDTF) Income Statement Analysis – Financial Results
- Orpea SA (0NEX.L) Income Statement Analysis – Financial Results
- Forrestania Resources Limited (FRS.AX) Income Statement Analysis – Financial Results
- CLASSYS Inc. (214150.KQ) Income Statement Analysis – Financial Results
Impel Pharmaceuticals Inc. (IMPL)
About Impel Pharmaceuticals Inc.
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 12.65M | 668.00K | 0.00 | 0.00 |
| Cost of Revenue | 6.50M | 691.00K | 0.00 | 0.00 |
| Gross Profit | 6.16M | -23.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 48.66% | -3.44% | 0.00% | 0.00% |
| Research & Development | 11.46M | 20.56M | 27.29M | 28.81M |
| General & Administrative | 77.89M | 50.90M | 18.05M | 12.75M |
| Selling & Marketing | 7.60M | 12.60M | 0.00 | 0.00 |
| SG&A | 77.89M | 50.90M | 18.05M | 12.75M |
| Other Expenses | -9.29M | -5.05M | -408.00K | -680.00K |
| Operating Expenses | 89.34M | 71.46M | 45.33M | 41.57M |
| Cost & Expenses | 95.84M | 72.15M | 45.33M | 41.57M |
| Interest Income | 10.58M | 2.25M | 0.00 | 417.00K |
| Interest Expense | 13.84M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.20M | 1.09M | 1.08M | 722.00K |
| EBITDA | -83.18M | -70.40M | -44.26M | -40.84M |
| EBITDA Ratio | -657.48% | -10,701.50% | 0.00% | 0.00% |
| Operating Income | -83.18M | -71.49M | -45.33M | -41.57M |
| Operating Income Ratio | -657.48% | -10,701.50% | 0.00% | 0.00% |
| Total Other Income/Expenses | -23.13M | -5.05M | -463.00K | -263.00K |
| Income Before Tax | -106.31M | -76.53M | -45.80M | -41.83M |
| Income Before Tax Ratio | -840.28% | -11,457.19% | 0.00% | 0.00% |
| Income Tax Expense | 23.13M | 2.00K | 1.00K | 30.00K |
| Net Income | -129.44M | -76.54M | -45.80M | -41.86M |
| Net Income Ratio | -1,023.08% | -11,457.49% | 0.00% | 0.00% |
| EPS | -5.52 | -5.24 | -3.49 | -3.19 |
| EPS Diluted | -5.52 | -5.24 | -3.49 | -3.19 |
| Weighted Avg Shares Out | 23.45M | 14.60M | 13.14M | 13.14M |
| Weighted Avg Shares Out (Dil) | 23.45M | 14.60M | 13.14M | 13.14M |
Impel NeuroPharma, Inc. (IMPL) CEO Adrian Adams on Q2 2021 Results - Earnings Call Transcript
Impel NeuroPharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update
Impel NeuroPharma Announces Publication of Pivotal Phase 3, Open-Label Stop 301 Study of INP104 (TRUDHESA™) for Treatment of Acute Migraine in the Journal Headache
Impel NeuroPharma Enters Into a $50 Million Debt Financing Agreement With Oxford Finance LLC and Silicon Valley Bank
Impel NeuroPharma Announces First Quarter 2021 Financial Results and Provides Business Update
Impel Neuropharma raises $80M in Washington state's first IPO of 2021
Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports